IC83/LY2603618
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IC83/LY2603618, covering 2018-10-19 to 2018-10-19. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer [Phase 1]